(hong kong, 21april 2020) tot biopharm international company limited (“tot biopharm” or the “company;” stock code: 1875.hk) is pleased to announce that dr. liu jun (“dr. liu”) has been appointed as the chief operating officer of the company (“coo”) with effect from 21 april 2020, supporting tot biopharm’s general manager, ms. yeh huang, chun ying, in promoting the development of overseas operations, and further speeding up the achievement of the company’s milestones.
mr. fu shan, chairman of tot biopharm, said “with dr. liu’s rich and seasoned experience and background, his appointment will be conducive to improving and enhancing internal collaboration between r&d and production in preparation for its entry into the phase of commercialization development in the near future, and, at the same time, strengthen the company’s exploration of overseas r&d and its international collaboration project, facilitate international strategic development layout.”
dr. liu joined tot biopharm on 17 october 2016. he is serving as the company’s executive director and chief scientific officer now, responsible for the research and development (“r&d”) of new products and product quality control. dr. liu has an extensive and relevant international education background. he has earned a ph.d. in bioanalytical chemistry from the university of california, davis in the united states and a bachelor’s degree in chemistry from the university of science & technology of china. he also has vast experience in r&d and management overseas and in china. he was the executive director of biologics research and development department in shanghai chempartner co., ltd., the senior scientist of bayer healthcare’s global biological drugs r&d center in berkeley, usa, and lead researcher in the immunology department at beckman research institute in california, usa.